

**14.09.2018**

**08:40 - 08:45 Welcome from the founders Room Scene AB**

08:40 - 08:45 **Welcome to MAP 2018**

F. André, Villejuif, FR

**08:45 - 10:35 Therapeutic targets Room Scene AB**

Moderation: E. Voest, Amsterdam, NL

08:45 - 09:05 **Head and neck**

K. Harrington, London, GB

09:05 - 09:25 **Genomic characterisation of metastatic breast cancers**

F. Bertucci, Marseille, FR

09:25 - 09:45 **Copy number alterations and breast cancers**

C. Caldas, Cambridge, GB

09:45 - 10:05 **Kidney cancer**

S. Turajlic, London, GB

10:05 - 10:25 **Molecular epidemiology of metastatic cancer: Data from DRUP trial**

E. Voest, Amsterdam, NL

10:25 - 10:35 **180 - Representative Sequencing: profiling extreme tumor diversity**

K. Litchfield, C. Swanton, S. Turajlic; London, GB

**10:35 - 10:55 Coffee break Foyer La Scene**

<b>10:55 - 12:45</b>	<b>Clonal evolution</b> Moderation: N. McGranahan, London, GB	<b>Room Scene AB</b>
10:55 - 11:15	<b>Clonal evolution in lung cancers</b> <u>N. McGranahan</u> , London, GB	
11:15 - 11:35	<b>APOBEC</b> <u>R. Harris</u> , Minneapolis, MN/US	
11:35 - 11:55	<b>Mutational processes</b> <u>S. Nik-Zainal</u> , Cambridge, GB	
11:55 - 12:15	<b>PDX</b> <u>S. Aparicio</u> , Vancouver, British Columbia/CA	
12:15 - 12:35	<b>Single cell/PDX</b> <u>S. Shah</u> , Vancouver, CA	
12:35 - 12:45	<b>590 - Preliminary results on mechanisms of resistance to ALK inhibitors: a prospective cohort from the MATCH-R study.</b> <u>G. Recondo</u> <sup>1</sup> , <u>L. Mezquita</u> <sup>1</sup> , <u>L. Bigot</u> <sup>1</sup> , <u>J. Galissant</u> <sup>1</sup> , <u>R. Frias</u> <sup>1</sup> , <u>F. André</u> <sup>1</sup> , <u>C. Massard</u> <sup>2</sup> , <u>J. Soria</u> <sup>1</sup> , <u>B. Besse</u> <sup>1</sup> , <u>L. Friboulet</u> <sup>1</sup> ; <sup>1</sup> Villejuif, FR, <sup>2</sup> Villejuif, CEDEX/FR	
<b>12:45 - 13:00</b>	<b>Lunch boxes</b>	<b>Room Scene AB</b>
<b>13:00 - 13:45</b>	<b>Industry satellite symposium 1</b>	<b>Room Scene AB</b>
<b>14:00 - 14:45</b>	<b>How to manage germline variance (Incl. consensus)</b> Moderation: A. Leary <sup>1</sup> , C. Turnbull <sup>2</sup> ; <sup>1</sup> Villejuif, FR, <sup>2</sup> London, GB	<b>Room Scene AB</b>
14:00 - 14:15	<b>Incidental findings in sequencing programs: What is the issue?</b> <u>T. Frébourg</u> , Rouen, FR	
14:15 - 14:35	<b>Presentation of consensus findings</b> <u>C. Turnbull</u> , London, GB	
14:35 - 14:45	<b>Panel discussion</b> <u>C. Turnbull</u> , London, GB	

<b>14:45 - 15:55</b>	<b>Precision medicine in gynaecological cancers and its implication outside the field</b>	<b>Room Scene AB</b>
	Moderation: A. Leary <sup>1</sup> , C. Turnbull <sup>2</sup> ; <sup>1</sup> Villejuif, FR, <sup>2</sup> London, GB	
14:45 - 15:05	<b>Biomarkers of homologous recombination deficiency</b> <u>A. Grigoriadis</u> , London, GB	
15:05 - 15:25	<b>Targeting DNA repair in gynecological cancers</b> <u>T. Helleday</u> , Stockholm, SE	
15:25 - 15:45	<b>Adoptive T cell therapy 2.0: Bringing cell therapy to common epithelial malignancies</b> <u>C. Klebanoff</u> , New York, NY/US	
15:45 - 15:55	<b>90 - Novel mechanism of platinum resistance: rapid selection of pre-existing BRCA1-proficient tumor cells during neoadjuvant chemotherapy (NACT) for ovarian cancer (OC) in BRCA1 germ-line mutation carriers</b> <u>E. Imyanitov</u> <sup>1</sup> , <u>E. Savonevich</u> <sup>2</sup> , <u>A. Ivantsov</u> <sup>1</sup> , <u>T. Gorodnova</u> <sup>1</sup> , <u>E. Preobrazhenskaya</u> <sup>1</sup> , <u>M. Kleshchov</u> <sup>1</sup> , <u>E. Kuligina</u> <sup>3</sup> , <u>A. Sokolenko</u> <sup>1</sup> ; <sup>1</sup> Saint-Petersburg, RU, <sup>2</sup> Grodno, BY, <sup>3</sup> Saint Petersburg, RU	
<b>15:55 - 16:20</b>	<b>Coffee break</b>	<b>Foyer La Scene</b>
<b>16:20 - 17:10</b>	<b>Keynote lecture 1</b> Moderation: F. André, Villejuif, FR	<b>Room Scene AB</b>
16:20 - 16:50	<b>Emergent and emerging kinase targets</b> <u>P. Parker</u> , London, GB	
16:50 - 17:10	<b>Q&amp;A</b>	
<b>17:10 - 18:10</b>	<b>What can applied mathematics bring to cancer precision medicine?</b>	<b>Room Scene AB</b>
17:10 - 17:30	<b>Numeric vision analyses</b> <u>N. Paragios</u> , Gif Sur Yvette, FR	
17:30 - 17:50	<b>AI in oncology</b> <u>J. Deasy</u> , New York, US	
17:50 - 18:10	<b>Q&amp;A</b>	
<b>18:15 - 19:00</b>	<b>Industry satellite symposium 2</b>	<b>Foyer La Scene</b>

**15.09.2018**

**08:30 - 10:00 MSI and immunotherapeutics** **Room Scene AB**  
Moderation: J.B.A.G. Haanen, Amsterdam, NL

08:30 - 08:50 **MSI: Basic science**  
M. Kloor, Heidelberg, DE

08:50 - 09:10 **MSI and immunotherapeutics**  
D. Le, Baltimore, MD/US

09:10 - 09:30 **Consensus on MSI/MMR determination to select patients eligible for anti-PD1**  
A. Scarpa, Verona, IT

09:30 - 09:50 **Clinical impact of MSI in colon cancers**  
J. Taberero, Barcelona, ES

09:50 - 10:00 **Q&A**  
J. Haanen, Amsterdam, NL

**10:00 - 10:45 Keynote lecture 2** **Room Scene AB**  
Moderation: F. André, Villejuif, FR

10:00 - 10:45 **Variant detection for precision medicine**  
N. López-Bigas, Barcelona, ES

**10:45 - 11:10 Coffee break** **Foyer La Scene**

**11:10 - 12:05 Precision immuno-oncology** **Room Scene AB**  
Moderation: J.B.A.G. Haanen, Amsterdam, NL

11:10 - 11:30 **Single T cell sequencing in breast cancer**  
S. Loi, Melbourne, VIC/AU

11:30 - 11:50 **Linking tumour genomics and efficacy of IT**  
N. Rizvi, New York, NY/US

11:50 - 12:05 **1110 - Mechanism informs precision: in vivo determinants of response to anti-CTLA-4 antibodies**  
A. Furness<sup>1</sup>, F. Arce Vargas<sup>1</sup>, K. Litchfield<sup>1</sup>, R. Rosenthal<sup>1</sup>, M. Gore<sup>2</sup>, J. Larkin<sup>1</sup>, S. Turajlic<sup>1</sup>, C. Swanton<sup>1</sup>, K. Peggs<sup>1</sup>, S. Quezada<sup>1</sup>; <sup>1</sup>London, GB, <sup>2</sup>Sw Jj, GB

**12:05 - 12:20 Lunch boxes** **Room Scene AB**

**12:20 - 13:05 Industry satellite symposium 3** **Room Scene AB**

<b>13:10 - 13:55</b>	<b>Keynote lecture 3</b> Moderation: J.B.A.G. Haanen, Amsterdam, NL	<b>Room Scene AB</b>
13:10 - 13:40	<b>Clonal hematopoiesis</b> <u>M. Manz</u> , Zürich, CH	
13:40 - 13:55	<b>Discussion</b>	
<b>14:00 - 15:00</b>	<b>Coffee and Poster walk/viewing</b>	<b>Room Scene AB</b>
14:00 - 14:00	<b>Early detection and diagnosis (Circulating DNA)</b>	
14:00 - 14:00	<b>1P - Application of liquid biopsies in metastatic gastrointestinal cancer to identify candidate therapeutic targets</b> <u>L. Pérez</u> <sup>1</sup> , P. Saiz López <sup>1</sup> , R. Sánchez-Escribano <sup>1</sup> , A. Rodrigo <sup>2</sup> , M. García González <sup>1</sup> , M. Durán <sup>3</sup> , M. Infante <sup>3</sup> , A. Terradez <sup>2</sup> , I. Faull <sup>4</sup> , E. Lastra <sup>5</sup> ; <sup>1</sup> Burgos, ES, <sup>2</sup> Paterna - Valencia, ES, <sup>3</sup> Valladolid, ES, <sup>4</sup> Barcelona, Barcelona/ES, <sup>5</sup> Burgos, Burgos/ES	
14:00 - 14:00	<b>2P - RETROSPHER. ERBB2 amplification detection in the plasma at diagnosis for early high-risk HER2-positive breast cancer.</b> <u>R. Sabatier</u> <sup>1</sup> , S. Garnier <sup>1</sup> , N. Carbuccia <sup>1</sup> , A. Guille <sup>1</sup> , C. Tarpin <sup>2</sup> , A. Goncalves <sup>2</sup> , D. Birnbaum <sup>1</sup> ; <sup>1</sup> Marseille, FR, <sup>2</sup> Marseille, CEDEX 9/FR	
14:00 - 14:00	<b>3P - Autotaxin: a possible new biological marker of endometrial cancer</b> <u>R. DE NOLA</u> <sup>1</sup> , E. Di Naro <sup>1</sup> , L.M. Schonauer <sup>1</sup> , M. Loverro <sup>2</sup> , T. Marrano <sup>1</sup> , A. Mazzocca <sup>1</sup> ; <sup>1</sup> Bari, IT, <sup>2</sup> Rome, IT	
14:00 - 14:00	<b>4P - Elevated plasma levels of hTERT mRNA and DNA in patients with gastric cancer in Northwest of Iran</b> <u>S.S. Hosseini-Asl</u> , H. Akhavan; Ardabil, IR	
14:00 - 14:00	<b>5P - Cell-free circulating BRAF V600 mutations analysis by biochip-based assay and droplet digital PCR in melanoma patients</b> <u>M. Emelyanova</u> , E. Telysheva, K. Orlova, I. Abramov, G. Snigiryova, O. Ryabaya, A. Zasedatelev; Moscow, RU	
14:00 - 14:00	<b>6P - NGS cfDNA data as a basis for development of simple RT-PCR diagnostic systems</b> <u>V. Mileyko</u> , D. Moiseenko, A. Grinchenko, E. Rozhavskaya, A. Kasianov; Moscow, RU	
14:00 - 14:00	<b>7P - Plasma ctDNA mutation analysis for identification of initial and acquired resistance to HER2-targeted therapy in advanced gastric cancer patients</b>	

E. Gaye<sup>1</sup>, B. Bellosillo Paricio<sup>2</sup>, L. Visa<sup>2</sup>, M. Iglesias Coma<sup>2</sup>, F. Sanchez Martin<sup>2</sup>, A. Sampera Borràs<sup>2</sup>, C. Montagut Viladot<sup>2</sup>; <sup>1</sup>Brest, BY, <sup>2</sup>Barcelona, ES

- 14:00 - 14:00 **8TiP - Circulating tumour DNA as an early marker of recurrence and treatment efficacy in ovarian carcinoma, the CIDOC study**  
R. Sabatier<sup>1</sup>, C. Pomel<sup>2</sup>, P. Colombo<sup>3</sup>, F. Narducci<sup>4</sup>, S. Garnier<sup>1</sup>, N. Carbuccia<sup>1</sup>, A. Guille<sup>1</sup>, D. Birnbaum<sup>1</sup>, C. Zemmour<sup>1</sup>, E. Lambaudie<sup>1</sup>; <sup>1</sup>Marseille, FR, <sup>2</sup>Clermont-Ferrand, FR, <sup>3</sup>Montpellier, FR, <sup>4</sup>Lille, FR
- 14:00 - 14:00 **Macroevolution and impact on treatment resistance**
- 14:00 - 14:00 **10P - EGFR T790M mutation in treatment-naïve tumor samples: low frequency, evidence for interaction with EGFR TKI-sensitizing mutations and lack of clear predictive value**  
E. Imyanitov<sup>1</sup>, A. Ivantsov<sup>1</sup>, E. Lavdovskaia<sup>1</sup>, A. Iyevleva<sup>1</sup>, N. Mitiushkina<sup>1</sup>, I. Bizin<sup>1</sup>, S. Orlov<sup>1</sup>, A. Togo<sup>1</sup>, F. Moiseyenko<sup>1</sup>, E. Levchenko<sup>2</sup>; <sup>1</sup>Saint-Petersburg, RU, <sup>2</sup>St. Petersburg, RU
- 14:00 - 14:00 **11P - Expression of erythropoietin receptor variant forms is associated with lymphatic invasion and metastasis formation in breast cancer**  
Z. Rakosy, Pécs, HU
- 14:00 - 14:00 **12P - Evaluation of Topoisomerase II, Ki-67 and P53 expression in non-muscle invasive urothelial carcinoma and their clinical significance**  
E. Elkhoully<sup>1</sup>, N. Alkady<sup>2</sup>, M. Soltan<sup>2</sup>; <sup>1</sup>Shebin El Kom, Menoufia Governorate/EG, <sup>2</sup>Shebin El Kom, EG
- 14:00 - 14:00 **13P - Expression of Her2-neu, SKP2 and HIF-1 and their role in predicting the response of muscle invasive urothelial carcinoma to bladder-preservation chemotherapy**  
E. Elkhoully<sup>1</sup>, N. Alkady<sup>2</sup>, A. Samir<sup>2</sup>; <sup>1</sup>Shebin El Kom, Menoufia Governorate/EG, <sup>2</sup>Shebin El Kom, EG
- 14:00 - 14:00 **14P - LINE-1 hypomethylation is a specific aberration in human hepatocellular carcinomas and correlates with shorter overall survival and CIMP-phenotypes**  
S.L. Anwar<sup>1</sup>, A. Vogel<sup>2</sup>, U. Lehmann<sup>2</sup>; <sup>1</sup>Yogyakarta, ID, <sup>2</sup>Hannover, DE
- 14:00 - 14:00 **15P - Investigation of the combined action of cisplatin and 6-phosphogluconate dehydrogenase inhibitor on pancreatic and lung cancer cell lines**  
D. Savenkova<sup>1</sup>, L. Minigulova<sup>1</sup>, K. Havrysh<sup>2</sup>, V. Skripova<sup>1</sup>, R. Kiyamova<sup>1</sup>; <sup>1</sup>Kazan, RU, <sup>2</sup>Kiev, UA
- 14:00 - 14:00 **16P - CD62L expression in chronic lymphocytic leukemia patients**  
E. Elkhoully<sup>1</sup>, W. Radwan<sup>2</sup>, M. Soliman<sup>2</sup>, S. Swelim<sup>2</sup>; <sup>1</sup>Shebin El Kom, Menoufia Governorate/EG, <sup>2</sup>Shebin El Kom, EG

- 14:00 - 14:00 **17P - Tumor Suppressor P53 Gene Codon 72 Polymorphism and Imatinib Cytogenetic Response in Chronic Myeloid Leukemia**  
E. Elkhoully<sup>1</sup>, K. Khalifa<sup>2</sup>, W. Radwan<sup>2</sup>, Y. Younis<sup>2</sup>; <sup>1</sup>Shebin El Kom, Menoufia Governorate/EG, <sup>2</sup>Shebin El Kom, EG
- 14:00 - 14:00 **New models and technologies for personalised medicine**
- 14:00 - 14:00 **19P - 100,000 Genomes Project: Cancer Programme**  
A. Sosinsky<sup>1</sup>, N. Murugaesu<sup>1</sup>, A. Hamblin<sup>2</sup>, J. Ambrose<sup>1</sup>, C. Turnbull<sup>1</sup>, S. Henderson<sup>1</sup>, A. Rueda-Martin<sup>1</sup>, T. Fowler<sup>1</sup>, M. Caulfield<sup>1</sup>, A. Rendon<sup>1</sup>; <sup>1</sup>London, GB, <sup>2</sup>Oxford, GB
- 14:00 - 14:00 **20P - The functional MDM4 genetic variant is associated with clinical outcome of lung adenocarcinoma patients with gefitinib treatment**  
N. Zhang<sup>1</sup>, M. Yang<sup>2</sup>, L. Zhang<sup>3</sup>, J. Liu<sup>2</sup>, H. Xing<sup>2</sup>; <sup>1</sup>Ji'nan, CN, <sup>2</sup>Jinan, CN, <sup>3</sup>Wuhan, CN
- 14:00 - 14:00 **21P - Evaluation of the TruSight Tumor 170 (TST170) assay and its value in clinical research**  
C. Heydt<sup>1</sup>, R. Pappesch<sup>2</sup>, K. Stecker<sup>3</sup>, J. Neumann<sup>4</sup>, R. Buettner<sup>1</sup>, S. Merkelbach-Bruse<sup>1</sup>; <sup>1</sup>Köln, DE, <sup>2</sup>Cologne, DE, <sup>3</sup>Heidelberg, DE, <sup>4</sup>Cambridge, GB
- 14:00 - 14:00 **22P - Head and Neck Squamous Cell Carcinoma organoids as a platform for personalized medicine.**  
E. Driehuis, S. Kolders, L. Devriese, S. Willems, H. Clevers, R. de Bree, E. de Ruiter; Utrecht, NL
- 14:00 - 14:00 **23P - Integrating Personalised Medicine into the Routine Cancer Diagnostic Pathway in Manchester, UK**  
J. Henry, J. Radford; Manchester, GB
- 14:00 - 14:00 **24P - Clinical outcomes in patients with advanced NSCLC treated with targeted therapies, with actionable mutations identified by InVisionFirst ctDNA assay.**  
J. Remon<sup>1</sup>, L. Mezquita<sup>1</sup>, S. Ortiz-Cuaran<sup>2</sup>, C. Jovelet<sup>1</sup>, L. Lacroix<sup>1</sup>, C. Morris<sup>3</sup>, E. Green<sup>4</sup>, P. Saintigny<sup>2</sup>, B. Besse<sup>1</sup>, A. Swalduz<sup>2</sup>, K. Howarth<sup>4</sup>, E. Rouleau<sup>1</sup>, F. De Kievit<sup>3</sup>, K. Baker-Neblett<sup>3</sup>, S. Roitt<sup>5</sup>, V. Plagnol<sup>4</sup>, M. Perol<sup>6</sup>, D. Planchard<sup>1</sup>; <sup>1</sup>Villejuif, FR, <sup>2</sup>Lyon, FR, <sup>3</sup>Great Abington, GB, <sup>4</sup>Cambridge, GB, <sup>5</sup>Abingdon, GB, <sup>6</sup>Lyon, CEDEX/FR
- 14:00 - 14:00 **25P - Leukocyte telomere length is associated with survival and drug resistance in lung adenocarcinoma patients treated with EGFR-TKIs**  
M. Yang<sup>1</sup>, J. Li<sup>1</sup>, N. Zhang<sup>2</sup>; <sup>1</sup>Jinan, CN, <sup>2</sup>Ji'nan, CN
- 14:00 - 14:00 **26P - Analysis of changes in the markers of DNA methylation in the process of complex treatment in acute myeloid leukemia in children**  
V. Rudenko, S. Kazakova, A. Tanas, V. Nemirovchenko, A. Popa, V. Strelnikov; Moscow, RU

- 14:00 - 14:00 **27P - PREDMED®**, a normalized expression signature of drug targets versus reference tissues aiming at generalizing treatment personalization  
L. Verlingue<sup>1</sup>, M. Baranger<sup>2</sup>, C. Gianesini<sup>2</sup>, J. Fritz<sup>2</sup>, M. Schaeffer<sup>2</sup>, D. Malka<sup>3</sup>, C. Jouffroy<sup>1</sup>, B. Loubaton<sup>2</sup>, D. Bagnard<sup>2</sup>; <sup>1</sup>Paris, FR, <sup>2</sup>Strasbourg, FR, <sup>3</sup>Villejuif, FR
- 14:00 - 14:00 **28P - Clinical impact of using a deep genomic profile in Carcinoma of Unknown Origin**  
A. Fernandez Díaz<sup>1</sup>, V. Iranzo<sup>1</sup>, S. Calabuig Fariñas<sup>1</sup>, E. Jantus<sup>1</sup>, A. Cunqueiro Tomas<sup>1</sup>, C. Avila Andrade<sup>1</sup>, S. Sauvage<sup>2</sup>, G. Beniuga<sup>3</sup>, C.J. Camps<sup>1</sup>; <sup>1</sup>Valencia, ES, <sup>2</sup>Gosselies, BE, <sup>3</sup>Charleroi, BE
- 14:00 - 14:00 **29P - Implementing molecular characterisation of prostate cancer tissue from patients recruited to the multi-centre STAMPEDE trial: the STRATOSPHERE consortium**  
E. Grist<sup>1</sup>, M. Parry<sup>1</sup>, L. Mendes<sup>1</sup>, S. Santos Vidal<sup>1</sup>, S. Kudahetti<sup>1</sup>, C. Gilson<sup>1</sup>, M. Anjum<sup>1</sup>, N. Atako<sup>1</sup>, F. Ingleby<sup>1</sup>, N. James<sup>2</sup>, N. Clarke<sup>3</sup>, M. Sydes<sup>1</sup>, M. Parmar<sup>1</sup>, S. Chowdhury<sup>1</sup>, R. Jones<sup>4</sup>, H. Leung<sup>4</sup>, R. Eeles<sup>5</sup>, D. Waugh<sup>6</sup>, D. Berney<sup>1</sup>, G. Attard<sup>1</sup>; <sup>1</sup>London, GB, <sup>2</sup>Birmingham, GB, <sup>3</sup>Salford, GB, <sup>4</sup>Glasgow, GB, <sup>5</sup>Sutton, GB, <sup>6</sup>Belfast, GB
- 14:00 - 14:00 **30P - Clinical validation and utility of InVision ctDNA in advanced non-small cell lung cancer (NSCLC) patients**  
J. Remon<sup>1</sup>, L. Mezquita<sup>1</sup>, D. Planchard<sup>1</sup>, C. Jovelet<sup>1</sup>, L. Lacroix<sup>1</sup>, E. Rouleau<sup>1</sup>, K. Howarth<sup>2</sup>, V. Plagnol<sup>2</sup>, C. Morris<sup>3</sup>, E. Green<sup>2</sup>, C. Le Pechoux<sup>1</sup>, C. Caramella<sup>1</sup>, J. Adam<sup>1</sup>, B. Besse<sup>1</sup>; <sup>1</sup>Villejuif, FR, <sup>2</sup>Cambridge, GB, <sup>3</sup>Great Abington, GB
- 14:00 - 14:00 **31P - MATCH-R development of preclinical models from patient with acquired resistance to targeted therapy**  
L. Bigot<sup>1</sup>, O. Deas<sup>2</sup>, G. Lang<sup>2</sup>, F. André<sup>1</sup>, S. Caro<sup>2</sup>, L. Friboulet<sup>1</sup>, Y. Loriot<sup>1</sup>, J. Judde<sup>2</sup>, B. Besse<sup>1</sup>, J. Soria<sup>1</sup>; <sup>1</sup>Villejuif, FR, <sup>2</sup>Evry, FR
- 14:00 - 14:00 **32P - A novel 4-gene prognostic signature for hypermutated colorectal cancer (CRC)**  
W. Ge, W. Cai, H. Hu; Hangzhou, CN
- 14:00 - 14:00 **33P - A nomogram for the prediction of KRAS mutation in colorectal cancer**  
W. Xiang, W. Dai, G. Cai; Shanghai, CN
- 14:00 - 14:00 **34P - Epigenomics paves a new way to assess potential toxicity and chemotherapeutic response of breast tumours to 5-fluorouracil**  
V. Strelnikov, E. Ignatova, T. Kekeeva, E. Poddubskaya, M. Nemtsova, E. Kuznetsova, D. Zaletaev, A. Tanas; Moscow, RU
- 14:00 - 14:00 **35P - Detection of ALK, RET, ROS1, NTRK1 and MET rearrangements and actionable mutations using Next Generation Sequencing in patients with Non-Small Cell Lung Cancer**

A. Harlé<sup>1</sup>, W. Dietmaier<sup>2</sup>, I. Vogl<sup>3</sup>, K. Neumann<sup>4</sup>, F. Haumaier<sup>5</sup>, A. Beggs<sup>6</sup>, V. Pestinger<sup>6</sup>, D. Grand<sup>7</sup>, A. Tallet<sup>8</sup>, J. Merlin<sup>1</sup>; <sup>1</sup>Vandoeuvre Les Nancy, CEDEX/FR, <sup>2</sup>Regensburg, DE, <sup>3</sup>Leipzig, DE, <sup>4</sup>Dessau, DE, <sup>5</sup>Bayreuth, DE, <sup>6</sup>Birmingham, GB, <sup>7</sup>Toulouse, FR, <sup>8</sup>Tours, FR

- 14:00 - 14:00 **37P - IgM anti-glycan antibodies in sera of colorectal cancer patients**  
A. Tikhonov, M. Chernichenko, V. Butvilovskaya, D. Sidorov, A. Rubina; Moscow, RU
- 14:00 - 14:00 **38P - Microarray based on Comparative Genomic Hybridization reveals new recurrent genetic aberrations in acute myeloid leukemia**  
J. Prada-Arismendy<sup>1</sup>, J. Lopez-Rivera<sup>2</sup>, Y. Carrillo<sup>2</sup>, E. Castillo<sup>3</sup>, W. Castellanos<sup>4</sup>;  
<sup>1</sup>Medellin, CO, <sup>2</sup>Bogotá, CO, <sup>3</sup>Envigado, CO, <sup>4</sup>Rionegro, CO
- 14:00 - 14:00 **39P - Clinical interpretation of lung cancer molecular profiles using rule-based artificial intelligence**  
D. Tihanyi<sup>1</sup>, C. Hegedüs<sup>1</sup>, E. Várkonyi<sup>1</sup>, R. Schwab<sup>1</sup>, I. Vályi-Nagy<sup>1</sup>, I. Peták<sup>1</sup>, L. Urbán<sup>2</sup>;  
<sup>1</sup>Budapest, HU, <sup>2</sup>Matrahaza, HU
- 14:00 - 14:00 **40P - Serum autoantibodies against tumor-associated antigen cyclin D1 represent a potential biomarker of malignancy in well-differentiated thyroid tumors**  
P. Belousov, A. Bogolyubova, P. Efimova, D. Demin, A. Abrosimov, K. Lanshchakov, V. Vanushko, A. Schwartz; Moscow, RU
- 14:00 - 14:00 **41P - Next Generation Sequencing (NGS) and patient pathways - What is the impact on clinical decision?**  
S. Coquerelle<sup>1</sup>, M. Darlington<sup>1</sup>, M. Morgane<sup>1</sup>, M. Durand<sup>1</sup>, J. Gutton<sup>1</sup>, I. Borgette<sup>2</sup>, S. Baffert<sup>1</sup>, P. Marino<sup>3</sup>, L. Perrier<sup>4</sup>, I. Durand-Zaleski<sup>1</sup>; <sup>1</sup>Paris, FR, <sup>2</sup>Villejuif, FR, <sup>3</sup>Marseille, FR, <sup>4</sup>Lyon, FR
- 14:00 - 14:00 **42P - Comparison of Expression of microRNAs which regulate Metastasis Genes in Breast Cancer Stem Cells and Primary Breast Cancer Tissues**  
M. Rahimi<sup>1</sup>, M. Ebrahimi<sup>2</sup>, E. Alizadeh<sup>1</sup>; <sup>1</sup>Tabriz, IR, <sup>2</sup>-, IR
- 14:00 - 14:00 **43P - 'Real world data' of genomic sequencing for personalised therapy**  
M. Bergamino<sup>1</sup>, A. Vethencourt<sup>2</sup>, A. Stradella<sup>2</sup>, S. Recalde<sup>2</sup>, C. Fabregat<sup>2</sup>, S. Vázquez<sup>2</sup>, C. Falo<sup>2</sup>, A. Fernández-Ortega<sup>2</sup>, R. Villanueva Vazquez<sup>3</sup>, M.E. Ferrer Cardona<sup>2</sup>, S. Rubio<sup>2</sup>, M. Gil-Gil<sup>2</sup>; <sup>1</sup>Barcelona, Barcelona/ES, <sup>2</sup>Barcelona, ES, <sup>3</sup>Malaga, ES
- 14:00 - 14:00 **44P - Correlation between an automated functional assay that predicts targeted agent (TA) sensitivity and the tumor response of the sorafenib treatment evaluated within the MOST clinical trial**  
O. Tredan<sup>1</sup>, O. Zelichov<sup>2</sup>, Z. Barbash<sup>2</sup>, Y. Daitsh<sup>2</sup>, L. Birnbaum<sup>2</sup>, G. Tarcic<sup>2</sup>, B. You<sup>3</sup>, P. Cassier<sup>4</sup>, C. de la Fouchardiere<sup>1</sup>, I. Ray-Coquard<sup>1</sup>, M. Brahmi<sup>5</sup>, Q. Wang<sup>1</sup>, V. Attignon<sup>4</sup>, C. Baudet<sup>4</sup>, G. Fournier Garin<sup>4</sup>, V. Agrapart<sup>4</sup>, A. Dargenio<sup>4</sup>, S. Chabaud<sup>4</sup>, D. Perol<sup>1</sup>, J. Blay<sup>1</sup>;  
<sup>1</sup>Lyon, CEDEX/FR, <sup>2</sup>Jerusalem, IL, <sup>3</sup>Pierre Bénite, CEDEX/FR, <sup>4</sup>Lyon, FR, <sup>5</sup>La Tronche, FR

- 14:00 - 14:00 **45P - Lessons from the routine tumor molecular profiling in Russia**  
V. Mileyko<sup>1</sup>, E. Rozhavskaya<sup>2</sup>, E. Veselovsky<sup>2</sup>, A. Kovtun<sup>2</sup>, M. Ivanov<sup>2</sup>, E. Ignatova<sup>2</sup>;  
<sup>1</sup>Novosibirsk, RU, <sup>2</sup>Moscow, RU
- 14:00 - 14:00 **46P - Potential prognostic markers for recurrence and survival in triple-negative breast cancer**  
K. Havrysh, G. Mukhametshina, S. Safina, S. Petrov, R. Kiyamova; Kazan, RU
- 14:00 - 14:00 **47P - "Characterization of the different cell population in primary culture of breast tumor"**  
B. Pattanayak<sup>1</sup>, G. Herrera<sup>1</sup>, I. Garrido-Cano<sup>1</sup>, A. Adam-Artigues<sup>1</sup>, E. Tormo<sup>1</sup>, B. Pineda Merlo<sup>1</sup>, P. Cabello<sup>1</sup>, A. Lluch<sup>2</sup>, P. Eroles<sup>2</sup>; <sup>1</sup>Valencia, ES, <sup>2</sup>Madrid, ES
- 14:00 - 14:00 **48P - Oncogenes and Cancer-Associated Thrombosis: is there a rationale for using molecular findings to assess thromboembolic risk in cancer patients?**  
L. Provenzano<sup>1</sup>, M. Platania<sup>2</sup>; <sup>1</sup>Milano, IT, <sup>2</sup>Milan, IT
- 14:00 - 14:00 **49TiP - Personalized neoadjuvant strategy in luminal A breast cancer to increase BCS rate (PLATO study)**  
W. Han, Seoul, KR
- 14:00 - 14:00 **Personalised medicine applied to immunotherapeutics**
- 14:00 - 14:00 **50P - A Novel Acetylated Derivative of Vitexin Improves the Immunogenic Profile of Breast Cancer Through Tuning miR-20a/MICA Axis**  
A. Awad<sup>1</sup>, R. Youness<sup>1</sup>, M. Ibrahim<sup>1</sup>, A. Abdelmotaal<sup>2</sup>, R. Assal<sup>1</sup>, M. Gad<sup>1</sup>; <sup>1</sup>Cairo, EG, <sup>2</sup>Abha, EG
- 14:00 - 14:00 **51P - DNA damage ATR/Chk1 checkpoint signalling increases PD-L1 immune checkpoint activation and its implication for personalised combination therapy**  
N. Kumar<sup>1</sup>, P. Yadav<sup>2</sup>, A. Kumar<sup>3</sup>, S. Beniwal<sup>2</sup>, A. Kapoor<sup>4</sup>, A. Kalwar<sup>5</sup>; <sup>1</sup>Boston, US/US, <sup>2</sup>Bikaner, IN, <sup>3</sup>Vadodara, IN, <sup>4</sup>Mumbai, IN, <sup>5</sup>Jodhpur, IN
- 14:00 - 14:00 **52P - Hedgehog pathway influence in the immune escape of tumor cells through PDL-1 modulation**  
F. Napolitano, C. Di Mauro, A. Pesapane, R. Rosa, V. D'Amato, A. Santaniello, A. Servetto, L. Formisano, R. Marciano, R. Bianco; Napoli, IT
- 14:00 - 14:00 **53P - miR-4317, a promising player tuning the anti-tumor armamentarium against Breast Cancer**  
R. Youness<sup>1</sup>, R. Assal<sup>1</sup>, A. Abdelmotaal<sup>2</sup>, M. Gad<sup>1</sup>; <sup>1</sup>Cairo, EG, <sup>2</sup>Abha, SA

- 14:00 - 14:00 **54P - Impact of HPV DNA and p16 on radical chemo-radiotherapy response in oropharyngeal cancer patients.**  
P. YADAV<sup>1</sup>, N. Kumar<sup>2</sup>, S. Beniwal<sup>1</sup>; <sup>1</sup>Bikaner, IN, <sup>2</sup>Naples, IT
- 14:00 - 14:00 **55P - TP53 mutations as predictor of response and longer survival under immune checkpoint inhibitors in advanced non-small lung cancer**  
S. Assoun<sup>1</sup>, N. Theou-Anton<sup>1</sup>, M. Nguenang<sup>1</sup>, A. Cazes<sup>1</sup>, C. Danel<sup>1</sup>, B. Abbar<sup>1</sup>, J. Pluvy<sup>1</sup>, V. Gounant<sup>2</sup>, A. Khalil<sup>1</sup>, C. Namour<sup>1</sup>, S. Brosseau<sup>1</sup>, G. Zalcman<sup>2</sup>; <sup>1</sup>Paris, FR, <sup>2</sup>Paris, CEDEX 18/FR
- 14:00 - 14:00 **56P - Quantification BCL6 tissue expression using FISH and immunohistochemistry in diffuse large B-cell lymphoma by digital image analysis**  
V. Kushnarev<sup>1</sup>, N. Matyashina<sup>2</sup>; <sup>1</sup>Saint-Petersburg, RU, <sup>2</sup> Saint Petersburg, RU
- 14:00 - 14:00 **57TiP - "PRIME STUDY": Searching for immune biomarkers in advanced castration resistant prostate cancer (CRPC) patients treated with standard therapy**  
N. Romero-Laorden<sup>1</sup>, A. Zapatero<sup>2</sup>, L. San Jose<sup>2</sup>, R. Lozano Mejorada<sup>3</sup>, M.I. Pacheco<sup>2</sup>, L. Rivera<sup>2</sup>, I. Hernandez<sup>2</sup>, I. Aragon<sup>2</sup>, T. González<sup>2</sup>, R. Colomer Bosch<sup>2</sup>; <sup>1</sup>Madrid, Madrid/ES, <sup>2</sup>Madrid, ES, <sup>3</sup>Salamanca, ES
- 14:00 - 14:00 **58TiP - TRIBE; Tyrosine Kinase Inhibitor Therapy in Renal-Cell Carcinoma: Immune Biomarker Evaluation**  
S. Villa<sup>1</sup>, M. Pillai<sup>1</sup>, D. Graham<sup>1</sup>, E. Kilgour<sup>1</sup>, N. Overton<sup>1</sup>, N. Vasudev<sup>2</sup>, A. Hughes<sup>1</sup>, A. Walker<sup>1</sup>, S. Dransfield<sup>1</sup>, F. Thistlethwaite<sup>1</sup>; <sup>1</sup>Manchester, GB, <sup>2</sup>Leeds, GB
- 14:00 - 14:00 **Therapeutic targets in cancer**
- 14:00 - 14:00 **60P - TRIB3: a new transcriptional target gene of rapalogs, modulating their effects on splicing**  
B. Stefanovska, C. Vicier, V. Scott, I. Bouakka, A. Rocca, F. André, O. Fromigué; Villejuif, FR
- 14:00 - 14:00 **61P - Chemotherapy after immunotherapy failure in patients with advanced gastrointestinal tumors**  
I. Baraibar Argota<sup>1</sup>, P. Martin Romano<sup>2</sup>, M. Sanmamed<sup>3</sup>, M. Rodríguez Ruiz<sup>1</sup>, I. Melero<sup>1</sup>, L. Resano<sup>1</sup>, A. Chopitea Ortega<sup>1</sup>, M. Ponz-Sarvisé<sup>1</sup>, E. Castanon Alvarez<sup>1</sup>; <sup>1</sup>Pamplona, ES, <sup>2</sup>Villejuif, FR, <sup>3</sup>New Haven, US
- 14:00 - 14:00 **62P - Identification of Resistance Mechanisms for EGFR-Targeted Therapy in Head and Neck Squamous Cell Carcinoma: Combining Whole-Exome Sequencing and Tumour Kinase Profiling**  
I. De Pauw<sup>1</sup>, A. Wouters<sup>2</sup>, J. Van den Bossche<sup>2</sup>, K. Op de Beeck<sup>2</sup>, M. Beyens<sup>2</sup>, H. Baysal<sup>2</sup>, P. Pauwels<sup>3</sup>, M. Peeters<sup>3</sup>, J. Vermorken<sup>3</sup>, F. Lardon<sup>2</sup>; <sup>1</sup>Antwerp, Antwerp/BE, <sup>2</sup>Wilrijk, BE, <sup>3</sup>Edegem, BE

- 14:00 - 14:00 **63P - Clinical impact of a comprehensive molecular approach in advanced gynecologic tumors.**  
F. Lefort<sup>1</sup>, C. Chakiba<sup>2</sup>, E. Khalifa<sup>1</sup>, S. Cousin<sup>2</sup>, Y. Laizet<sup>3</sup>, S. Croce<sup>3</sup>, T. Grellety<sup>2</sup>, A. Italiano<sup>2</sup>, A. Floquet<sup>2</sup>, I. Soubeyran<sup>2</sup>; <sup>1</sup>Bordeaux, FR, <sup>2</sup>Bordeaux, CEDEX/FR, <sup>3</sup>Bordeaux Cedex, FR
- 14:00 - 14:00 **64P - Regulating rs2278414 (G/A) disease-associated SNP in ZNF350 3'UTR by miR-150-5p: A step towards Personalised Therapy in Breast Cancer**  
E. Fouad, R. Youness, R. Assal, M. Gad; Cairo, EG
- 14:00 - 14:00 **65P - FLYWCH1, a novel transcription factor with tumor suppressor activity**  
S. Almozyan, Nottingham, GB
- 14:00 - 14:00 **66P - Adapting a prescreening program to match molecular alterations in over 5,000 patient's tumors with targeted agents and immunotherapies in early clinical trials over the last 8 years**  
S. Aguilar, A. Vivancos, P. Nuciforo, C. Viaplana, F. Ruiz-Pace, E. Sanchez, J. Rodon, J. Taberner, E. Garralda, R. Dienstmann; Barcelona, ES
- 14:00 - 14:00 **67P - Association BRCA mutation status between BMN 673 (talazoparib), an oral PARP inhibitor, in triple-negative breast cancer**  
G. Guney Eskiler<sup>1</sup>, G. Cecener<sup>2</sup>, U. Egeli<sup>2</sup>, B. Tunca<sup>2</sup>; <sup>1</sup>Sakarya, TR, <sup>2</sup>Bursa, TR
- 14:00 - 14:00 **68P - Differences in expression profiling and biomarkers between histological colorectal carcinoma[s] subsets from the serrated pathway.**  
M.M. Kot<sup>1</sup>, J. Garcia-Solano<sup>1</sup>, M.D.C. Turpin<sup>2</sup>, F. Garcia-Garcia<sup>3</sup>, R. Carbonell-Muñoz<sup>1</sup>, B. Alburquerque Gonzalez<sup>1</sup>, D. Torres-Moreno<sup>1</sup>, A. Conesa<sup>3</sup>, P. Conesa-Zamora<sup>4</sup>; <sup>1</sup>Cartagena, ES, <sup>2</sup>Madrid, ES, <sup>3</sup>Valencia, ES, <sup>4</sup>Murcia, ES
- 14:00 - 14:00 **69P - Molecular profiling of tumour and ctDNA in a gastrointestinal cancer cohort at an academic cancer centre**  
S. Rack, G. Brady, A. Wallace, M. Galvin, K. Frese, M. Krebs, C. Dive, D. Rothwell, M. Ayub, N. Cook; Manchester, GB
- 14:00 - 14:00 **70P - Emerging role of FAT1 gene in the Regulation of oncogenic miRNA 221/222- 3p in glioma**  
N. Malik, P. Chattopadhyay, C. Sarkar, A. Suri, S. Sinha, K. Chosdol; Delhi, IN
- 14:00 - 14:00 **71P - Role of ATDC gene as a biomarker of Doxorubicin response in Triple-Negative Breast Cancer**  
R. Cervera Vidal, C. Lozano Asencio, R. Tébar Martinez, F. Martinez Martinez, J. Forés Martos, J. Climent Bataller; Valencia, ES
- 14:00 - 14:00 **72P - Gli promotes tumor progression and metastasis through regulating EMT in non-small-cell lung cancer**  
L. Jiang<sup>1</sup>, S. Jiang<sup>1</sup>, L. Wang<sup>2</sup>; <sup>1</sup>Shanghai, CN, <sup>2</sup>Shijiazhuang, CN

- 14:00 - 14:00 **73P - Role of miR-449 family on doxorubicin-based chemotherapy response in triple-negative breast cancer**  
E. Tormo Martin<sup>1</sup>, A. Adam-Artigues<sup>1</sup>, I. Garrido-Cano<sup>1</sup>, B. Pineda Merlo<sup>1</sup>, B. Pattanayak<sup>1</sup>, P. Cabello<sup>1</sup>, J. Albanell<sup>2</sup>, F. Rojo<sup>3</sup>, A. Lluch<sup>1</sup>, P. Eroles<sup>1</sup>; <sup>1</sup>Valencia, ES, <sup>2</sup>Barcelona, ES, <sup>3</sup>Madrid, ES
- 14:00 - 14:00 **74P - Mutations in TSC1/TSC2 genes are prevalent in sporadic renal angiomyolipoma and insulinoma tumors, supporting their responsiveness to mTOR inhibitors.**  
K. Anoshkin, I. Vasilyev, C. Mosyakova, A. Tanas, K. Karandasheva, N. Bagmet, G. Karagyozyan, Y. Doludin, E. Kuznetsova, L. Gurevich, A. Vinarov, D. Zaletaev, M. Sekacheva, V. Strelnikov; Moscow, RU
- 14:00 - 14:00 **75P - Synthetic Lethal Effects of BMN 673 loaded Solid Lipid Nanoparticles on Triple-Negative Breast Cancer**  
G. Guney Eskiler<sup>1</sup>, G. Cecener<sup>2</sup>, U. Egeli<sup>2</sup>, B. Tunca<sup>2</sup>; <sup>1</sup>Sakayra, TR, <sup>2</sup>Bursa, TR
- 14:00 - 14:00 **76P - Targeting p63 upregulation may prevent the development of MAPK inhibitor resistance in melanoma**  
T. Borg, A. Patel, D. Bergamaschi, C. Harwood; London, GB
- 14:00 - 14:00 **77P - The reduction of the expression of B-catenin and c-Myc is related to a better outcome in patients with AML**  
A. Cardona<sup>1</sup>, J. Prada-Arismendy<sup>2</sup>, E. Castillo<sup>3</sup>, J. Arroyave<sup>2</sup>; <sup>1</sup>Medellín, CO, <sup>2</sup>Medellin, CO, <sup>3</sup>Envigado, CO
- 14:00 - 14:00 **78P - Leukotriene B4 receptors as a therapeutic target for triple-negative breast cancer**  
A. Kalinkin, V. Strelnikov, E. Ignatova, T. Kekeeva, M. Nemtsova, D. Zaletaev, E. Poddubskaya, E. Kuznetsova, A. Tanas; Moscow, RU
- 14:00 - 14:00 **79P - Wnt-signaling pathway in the cancer stem cells of glioblastoma**  
I. Bryukhovetskiy<sup>1</sup>, V. Shevchenko<sup>2</sup>, Y. Khotimchenko<sup>1</sup>; <sup>1</sup>Vladivostok, RU, <sup>2</sup>Moscow, RU
- 14:00 - 14:00 **80P - TRK wild-type and fusion protein expression in solid tumors: characterization by immunohistochemistry and in situ hybridization**  
J. Feng<sup>1</sup>, K. Ebata<sup>2</sup>, F. Hansen<sup>1</sup>, L. Kivi<sup>1</sup>, C. Kriegshauser<sup>1</sup>, D. Morosini<sup>2</sup>, T. Shen<sup>1</sup>, A. Sireci<sup>3</sup>, P. Thorne-Nuzzo<sup>1</sup>, B. Tuch<sup>3</sup>; <sup>1</sup>Tucson, AZ/US, <sup>2</sup>Stamford, CT/US, <sup>3</sup>Stamford, US
- 14:00 - 14:00 **81P - EPHA2/MAPK pathway confers acquired resistance of afatinib in gastric cancer**  
Z. Chen, Z. Liu, J. Gao, L. Shen; Beijing, CN
- 14:00 - 14:00 **82P - The clinical impact of miRNA34a and P53 gene expression in colon cancer**

S. Gohar<sup>1</sup>, E. Badr<sup>2</sup>, M. Assar<sup>2</sup>, M. Badr<sup>2</sup>, R. Hathout<sup>2</sup>, S. El-Kousy<sup>2</sup>; <sup>1</sup>Shebin El Kom, Menoufia Governorate/EG, <sup>2</sup>Shebin El Kom, EG

- 14:00 - 14:00 **83P - Comparing clonality between components of combined hepatocellular carcinoma and cholangiocarcinoma by targeted sequencing**  
N. Yoon, J. Jeon; Incheon, KR
- 14:00 - 14:00 **85P - The role of Topoisomerase II- $\alpha$  (TOPO IIA) as a predictive factor for response to neoadjuvant anthracyclines based chemotherapy in locally advanced breast cancer.**  
M. Gamea, Aswan, EG
- 14:00 - 14:00 **86P - Does the long noncoding RNA HULC act as a sponge or as a downstream target for miR-186 in hepatocellular carcinoma?**  
D. Habashy, K. Hosny, G. Esmat, A. Abdelaziz; Cairo, EG
- 14:00 - 14:00 **87P - Mir-506-3p Synergistically Represses Breast Cancer Progression Through Altering Cell Cycle Regulators**  
G. Saad El Din, R. Youness, R. Assal, M. Gad; Cairo, EG
- 14:00 - 14:00 **88P - Crosstalk Between Hesperetin and miR-486-5p in Triple-Negative Breast Cancer (TNBC): An Approach Towards Precision Medicine**  
R. Abdallah<sup>1</sup>, R. Youness<sup>1</sup>, N. El Meckawy<sup>1</sup>, A. El Sebaaei<sup>1</sup>, A. Abdelmotaal<sup>2</sup>, R. Assal<sup>1</sup>; <sup>1</sup>Cairo, EG, <sup>2</sup>Abha, EG
- 14:00 - 14:00 **90P - Prognostic value of immune gene's expression in head and neck squamous cell carcinoma patients**  
C. Lecerf<sup>1</sup>, M. Kamal<sup>1</sup>, S. Vacher<sup>1</sup>, W. Chemlali<sup>1</sup>, C. Dubot<sup>2</sup>, E. Jeannot<sup>1</sup>, J. Klijanienko<sup>1</sup>, C. Hoffmann<sup>1</sup>, I. Bieche<sup>1</sup>, C. Le Tourneau<sup>1</sup>; <sup>1</sup>Paris, FR, <sup>2</sup>St. Cloud, FR
- 14:00 - 14:00 **91P - A major response to carboplatin in a metastatic triple-negative breast cancer patient with somatic mutation of BRCA1 and RAD51B: when chemotherapy meets precision medicine.**  
L. Seguin, M. Chaffanet, R. Sabatier, A. Jose, S. Garnier, N. Carbuccia, A. Guille, D. Birnbaum, F. Bertucci, A. Goncalves; Marseille, FR
- 14:00 - 14:00 **92P - Next-Generation Sequencing reveals high intra-individual molecular concordance between primary head and neck tumors and matched local or distant recurrences.**  
N. Martin<sup>1</sup>, N. Ebran-Bendahhou<sup>1</sup>, J. Boyer<sup>1</sup>, V. Duranton-Tanneur<sup>1</sup>, A. Bozec<sup>1</sup>, F. Peyrade<sup>1</sup>, J. Guigay<sup>2</sup>, A. Sudaka-Bahadoran<sup>1</sup>, G. Milano<sup>1</sup>, E. Saada-Bouزيد<sup>1</sup>; <sup>1</sup>Nice, FR, <sup>2</sup>Nice, CEDEX 2/FR
- 14:00 - 14:00 **93P - Decreasing telomerase activity of adenocarcinoma cancer cell line (AGS) is associated with different concentrations of sodium selenite and cadmium chloride and selenium l methionine**  
S.S. Hosseini-Asl, A. Fazabakhsh, M. Sagha; Ardabil, IR

- 14:00 - 14:00 **94P - Molecular testing of gliomas**  
D. Konvalinka, R. Mech, I. Urbanovska, O. Motyka, M. Smolikova, J. Simova, S. Pitronova, J. Zmolikova, M. Uvirova, J. Dvorackova; Ostrava, CZ
- 14:00 - 14:00 **95P - First report of ZNF518B gene expression as a prognostic factor in colorectal cancer development. Role in tissue invasiveness.**  
F. Valiente<sup>1</sup>, A. Riffo-Campos<sup>2</sup>, A. Cervantes<sup>1</sup>, G. López-Rodas<sup>1</sup>, L. Franco<sup>1</sup>, J. Castillo<sup>1</sup>; <sup>1</sup>Valencia, ES, <sup>2</sup>Temuco, CL
- 14:00 - 14:00 **96P - ERBB2 and PI3KCA mutations in endocrine resistant breast cancer (BC)**  
M. Venturelli, A. Toss, F. Piacentini, I. Bernardis, E. Tenedini, C. Omarini, L. Moscetti, S. Cascinu, E. Tagliafico, L. Cortesi; Modena, IT
- 14:00 - 14:00 **97P - RANK expression predicts long term outcome in early Luminal breast cancer**  
L. Kassem<sup>1</sup>, P. Clézardin<sup>2</sup>, I. Treilleux<sup>2</sup>; <sup>1</sup>Giza, EG, <sup>2</sup>Lyon, FR
- 14:00 - 14:00 **98P - Customized or randomized trials for relapsed refractory pediatric Burkitt lymphomas? A retrospective analysis of two clinical cases with comprehensive molecular profiling - possible explanation for different treatment outcomes after similar targeted therapies.**  
K. Polaskova<sup>1</sup>, A. Martincekova<sup>1</sup>, Z. Krenova<sup>1</sup>, D. Valik<sup>1</sup>, H. Noskova<sup>1</sup>, O. Slaby<sup>1</sup>, V. Kanderova<sup>2</sup>, O. Hrusak<sup>2</sup>, G. Klement<sup>3</sup>, J. Neradil<sup>1</sup>, R. Veselska<sup>1</sup>, J. Sterba<sup>1</sup>; <sup>1</sup>Brno, CZ, <sup>2</sup>Prague, CZ, <sup>3</sup>Toronto, CA
- 14:00 - 14:00 **99P - Molecular treatment stratification in second-line treatment of pancreatic adenocarcinoma: PePaCaKa-001**  
M. Kordes<sup>1</sup>, M. Löhr<sup>1</sup>, L. Malgerud<sup>1</sup>, S. Kaduthanam<sup>2</sup>, J. Frödin<sup>1</sup>, M. Karimi<sup>1</sup>, J. Yachnin<sup>1</sup>, C. Fernandez Moro<sup>1</sup>, S. Ghazi<sup>1</sup>, R. Heuchel<sup>1</sup>, V. Wirta<sup>3</sup>, C. Hülsewig<sup>2</sup>, K. Stecker<sup>2</sup>, M. Del Chiaro<sup>1</sup>, A. Östman<sup>1</sup>, L. Engstrand<sup>3</sup>, S. Brock<sup>2</sup>, M. Gustafsson-Liljefors<sup>1</sup>; <sup>1</sup>Stockholm, SE, <sup>2</sup>Heidelberg, DE, <sup>3</sup>Solna, SE
- 14:00 - 14:00 **100P - RPS6 through the activation of NRF2 causes resistance to antiHER2 drugs in HER2 amplified gastric cancer (GC) models.**  
V. Gambardella<sup>1</sup>, F. Valiente<sup>2</sup>, N. Tarazona<sup>2</sup>, D. Roda<sup>2</sup>, P. Tolosa<sup>2</sup>, T. Fleitas Kanonnikoff<sup>2</sup>, B. Garcia Mico<sup>2</sup>, M. Huerta<sup>2</sup>, S. Rosello<sup>2</sup>, C. Martinez-Ciarpaglini<sup>2</sup>, A. Cervantes<sup>2</sup>, J. Castillo<sup>2</sup>; <sup>1</sup>Valencia, Valencia/ES, <sup>2</sup>Valencia, ES
- 14:00 - 14:00 **101P - Involvement of miR-99a in resistance to chemotherapy in triple-negative breast cancer**  
I. Garrido-Cano<sup>1</sup>, B. Pattanayak<sup>1</sup>, A. Adam-Artigues<sup>1</sup>, P. Cabello<sup>1</sup>, B. Pineda<sup>1</sup>, E. Tormo<sup>1</sup>, J. Albanell<sup>2</sup>, F. Rojo<sup>3</sup>, A. Lluch<sup>3</sup>, P. Eroles<sup>3</sup>; <sup>1</sup>Valencia, ES, <sup>2</sup>Barcelona, ES, <sup>3</sup>Madrid, ES
- 14:00 - 14:00 **102P - Muscleblind-like 1 regulates epithelial to mesenchymal transition markers in triple-negative breast cancer**

A. Adam Artigues<sup>1</sup>, E. Tormo<sup>1</sup>, E. Cerro-Herreros<sup>2</sup>, M. Sabater<sup>1</sup>, I. Garrido-Cano<sup>1</sup>, B. Pineda Merlo<sup>1</sup>, B. Pattanayak<sup>1</sup>, P. Cabello<sup>1</sup>, R. Artero<sup>1</sup>, P. Eroles<sup>1</sup>; <sup>1</sup>Valencia, ES, <sup>2</sup>Burjassot, València, ES

- 14:00 - 14:00 **104P - Study of toxicity of the conventional treatments in myeloproliferative neoplasms, based on the functional status of the RUNX1/CBF-BETA/P300/HIPK2 complex**  
C. Lozano Asencio, R. Cervera Vidal, J. Climent Bataller, J.C. Hernández Boluda; Valencia, ES
- 14:00 - 14:00 **105P - Glycolytic enzymes Lactate Dehydrogenase A (LDHA) and Phosphofructokinase P (PFKP) are good biomarkers of survival and potential therapeutic targets in cervical cancer**  
L. BOLAÑOS, A. Espinoza, A. Alfaro, E. Barron, E. Juárez, J. Berumen Campos; Ciudad De México, MX
- 14:00 - 14:00 **106P - Experience of 22 patients with ROS mutated lung adenocarcinoma treated with crizotinib at tertiary care center in India**  
V. Talreja, N. Pande; Mumbai, IN
- 14:00 - 14:00 **107P - Computational integrative analysis of identification of potential therapeutic genes and networks in breast cancer.**  
M. Peer Mohammed<sup>1</sup>, V. Parthasarathy<sup>2</sup>; <sup>1</sup>Chennai, IN, <sup>2</sup>Coimbatore, IN
- 14:00 - 14:00 **108P - The effect of the seleno-L-methionin, sodium selenite and cadmium chloride on telomerase activity of chick embryo neural tube cells**  
H. Akhavan<sup>1</sup>, S.S. Hosseini-Asl<sup>2</sup>, H. Abbasgholizadeh<sup>2</sup>, M. Sagha<sup>2</sup>; <sup>1</sup>Rasht, IR, <sup>2</sup>Ardabil, IR
- 14:00 - 14:00 **109P - PARP inhibitor (PARPi) monotherapy treatment in non-BRCA and/or non-serous gynaecological cancers**  
A. Ryan, S. Cruz, R. Miller, R. Kristeleit; London, GB
- 14:00 - 14:00 **110TiP - PREvalence of BRCA mutations and correlations with Demographic and clinical characteristicS in paTients with ovarian, fallopian tube or primary peritoneal cancer in Romania (PREDICT)**  
C. Cebotaru<sup>1</sup>, D. Stanculeanu<sup>2</sup>, D. Median<sup>2</sup>; <sup>1</sup>Cluj-Napoca, RO, <sup>2</sup>Bucharest, RO
- 14:00 - 14:00 **Tumour microenvironment**
- 14:00 - 14:00 **113P - Plasminogen Activator Inhibitor-1 promotes immunosuppression in cancer by modulating immune component of tumor microenvironment.**  
P. YADAV<sup>1</sup>, N. Kumar<sup>2</sup>, A. Kumar<sup>3</sup>, A. Kapoor<sup>4</sup>, S. Beniwal<sup>1</sup>, A. Kalwar<sup>5</sup>; <sup>1</sup>Bikaner, IN, <sup>2</sup>Naples, IT, <sup>3</sup>Vadodara, IN, <sup>4</sup>Mumbai, IN, <sup>5</sup>Jodhpur, IN

14:00 - 14:00 **114P - Comprehensive analysis for immune profiles of tumor microenvironment in lung adenocarcinomas: Prognostic effect of immunomodulatory molecules**

K. Takamochi<sup>1</sup>, M. Hosoya<sup>1</sup>, K. Mogushi<sup>1</sup>, T. Hayashi<sup>1</sup>, M. Ito<sup>2</sup>, H. Kawaji<sup>3</sup>, Y. Hayashizaki<sup>4</sup>, K. Suzuki<sup>1</sup>; <sup>1</sup>Tokyo, JP, <sup>2</sup>Yokohama, JP, <sup>3</sup>Yokohama, JP, <sup>4</sup>Yokohama, L/JP

14:00 - 14:00 **115P - GNMT negatively regulates MAPK Pathway and suppresses the growth and metastasis of Hepatocellular cancer cells**

S. Jiang, L. Jiang, J. Fang; Shanghai, CN

**15:00 - 16:15 Innovative clinical trials** **Room Scene AB**  
Moderation: S. Peters, Lausanne, CH

15:00 - 15:20 **Genomic-driven trials**

R. Dienstmann, Barcelona, ES

15:20 - 15:40 **Switching a cold into hot tumour: The TONIC trial**

M. Kok, Amsterdam, NL

15:40 - 16:00 **(Anti-)angiogenesis together with immunotherapeutics (IMpower data)**

S. Peters, Lausanne, CH

16:00 - 16:15 **1120 - Immune classification of soft tissue sarcoma and its association with molecular characteristics, and clinical outcome**

F. Petitprez<sup>1</sup>, A. de Reyniès<sup>1</sup>, T. Chen<sup>2</sup>, C. Sun<sup>1</sup>, L. Lacroix<sup>1</sup>, J. Adam<sup>3</sup>, M. Toulmonde<sup>4</sup>, A. Italiano<sup>5</sup>, C. Sautès-Fridman<sup>1</sup>, W. Fridman<sup>1</sup>; <sup>1</sup>Paris, FR, <sup>2</sup>Taipei, TW, <sup>3</sup>Villejuif, FR, <sup>4</sup>Bordeaux, FR, <sup>5</sup>Bordeaux, CEDEX/FR

**16:15 - 17:15 Linking infectious disease and cancer: Impact on cancer precision medicine** **Room Scene AB**  
Moderation: F. André, Villejuif, FR

16:15 - 16:40 **Microbiota**

L. Zitvogel, Villejuif, FR

16:40 - 17:05 **Inflammation and cancer precision medicine**

A. Mantovani, Milan, IT

17:05 - 17:15 **Discussion**